Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FATE Stock Forecast 2026-2027
$2.06
Current Price
$240.11M
Market Cap
Buy 6
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to FATE Price Targets
+288.3%
To High Target of $8.00
+191.3%
To Median Target of $6.00
+6.8%
To Low Target of $2.20
FATE Price Momentum
+4.0%
1 Week Change
+8.4%
1 Month Change
+62.2%
1 Year Change
+110.2%
Year-to-Date Change
-28.5%
From 52W High of $2.88
+126.4%
From 52W Low of $0.91
📊 TOP ANALYST CALLS
Did FATE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Fate Therapeutics is one of their latest high-conviction picks.
Latest FATE Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, FATE has a neutral consensus with a median price target of $6.00 (ranging from $2.20 to $8.00). The overall analyst rating is Buy (7.8/10). Currently trading at $2.06, the median forecast implies a 191.3% upside. This outlook is supported by 6 Buy, 6 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FATE Analyst Ratings
6
Buy
6
Hold
0
Sell
FATE Price Target Range
Low
$2.20
Average
$6.00
High
$8.00
Current: $2.06
Latest FATE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FATE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $7.00 |
| May 4, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 31, 2025 | HC Wainwright & Co. | Buy | Upgrade | $N/A | |
| Oct 27, 2025 | Wedbush | Outperform | Upgrade | $N/A | |
| Oct 27, 2025 | Needham | Hold | Reiterates | $N/A | |
| Aug 13, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Jun 12, 2025 | Needham | Hold | Reiterates | $N/A | |
| May 14, 2025 | Barclays | Overweight | Maintains | $N/A | |
| May 14, 2025 | Baird | Neutral | Maintains | $N/A | |
| May 14, 2025 | Needham | Hold | Reiterates | $N/A | |
| Mar 6, 2025 | Stifel | Hold | Maintains | $N/A | |
| Mar 6, 2025 | Wedbush | Neutral | Reiterates | $N/A | |
| Mar 6, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Mar 6, 2025 | Needham | Hold | Reiterates | $N/A | |
| Nov 19, 2024 | Needham | Hold | Reiterates | $N/A | |
| Nov 13, 2024 | Needham | Hold | Reiterates | $N/A | |
| Aug 22, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Aug 14, 2024 | Needham | Hold | Reiterates | $N/A | |
| Jun 17, 2024 | Piper Sandler | Overweight | Upgrade | $N/A | |
| May 16, 2024 | HC Wainwright & Co. | Neutral | Maintains | $N/A |
Fate Therapeutics Inc. (FATE) Competitors
The following stocks are similar to Fate Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Fate Therapeutics Inc. (FATE) Financial Data
Fate Therapeutics Inc. has a market capitalization of $240.11M with a P/E ratio of -1.8x. The company generates $6.32M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -20.3% quarter-over-quarter, while maintaining an operating margin of -2,540.4% and return on equity of -55.5%.
Valuation Metrics
Market Cap
$240.11M
Enterprise Value
$119.93M
P/E Ratio
-1.8x
PEG Ratio
0.1x
Price/Sales
36.4x
Growth & Margins
Revenue Growth (YoY)
-20.3%
Gross Margin
N/A
Operating Margin
-2,540.4%
Net Margin
0.0%
EPS Growth
-20.3%
Financial Health
Cash/Price Ratio
+72.8%
Current Ratio
5.9x
Debt/Equity
42.7x
ROE
-55.5%
ROA
-25.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Fate Therapeutics Inc. (FATE) Business Model
About Fate Therapeutics Inc.
What They Do
Develops off-the-shelf cellular immunotherapies.
Business Model
The company operates in the biopharmaceutical sector, focusing on the development of off-the-shelf cellular immunotherapies utilizing induced pluripotent stem cell (iPSC) technology. It generates revenue through the advancement of its clinical pipeline, which includes several candidates targeting various cancers and autoimmune diseases. Successful clinical trials and subsequent approvals can lead to partnerships, licensing agreements, and ultimately, product sales.
Additional Information
Fate Therapeutics' pipeline includes promising candidates such as FT819, FT825, FT836, and FT522, which aim to address significant medical needs in oncology and immunology. The company's innovative approach strives to simplify the delivery of cell therapies, enabling outpatient administration and same-day discharge, which could enhance patient accessibility and treatment adherence.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
181
CEO
Dr. Bahram Valamehr M.B.A., Ph.D.
Country
United States
IPO Year
2013
Website
www.fatetherapeutics.comFate Therapeutics Inc. (FATE) Latest News & Analysis
Latest News
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11 days ago
Quick Summary
Fate Therapeutics granted 67,300 RSUs to two new non-executive employees as part of its equity plan. The RSUs vest over four years, contingent on continued employment.
Why It Matters
Fate Therapeutics' RSU grant signals confidence in attracting talent, crucial for advancing their iPSC therapies. This could enhance operational capabilities and impact future growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fate Therapeutics (NASDAQ: FATE) reported positive results for its off-the-shelf CAR T-cell therapies FT819 and FT839 at EULAR 2026, showing effective treatment in SLE patients and promising preclinical results in rheumatoid arthritis.
Why It Matters
FT819's promising results in treating systemic lupus erythematosus (SLE) suggest a potential breakthrough in autoimmune therapies, which could significantly enhance Fate Therapeutics' market position and investor value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fate Therapeutics' FT836 shows significant lesion reduction in metastatic colorectal cancer without conditioning chemotherapy. Data presented at ASCO 2026 highlights its potential for advanced solid tumors.
Why It Matters
FT836's promising Phase 1 results in metastatic colorectal cancer without chemotherapy could revolutionize treatment, potentially boosting Fate Therapeutics' stock and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fate Therapeutics (NASDAQ: FATE) will present data on its off-the-shelf CAR T-cell programs at the ASCO Annual Meeting in Chicago (May 29 - June 2, 2026) and EULAR in London (June 3-6, 2026).
Why It Matters
Fate Therapeutics' data presentation at major conferences can boost investor confidence, influence stock performance, and attract interest in its innovative CAR T-cell programs.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
RECLAIM – LN, a Phase 2 clinical trial for FT819 targeting refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis, is set to begin in the second half of 2026.
Why It Matters
The initiation of the RECLAIM trial for FT819 indicates progress in treating lupus nephritis, potentially impacting market perception and investor sentiment in biotech and pharmaceutical sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fate Therapeutics reported a quarterly loss of $0.26 per share, better than the Zacks Consensus Estimate of $0.29, and improved from a loss of $0.32 per share a year earlier.
Why It Matters
Fate Therapeutics' smaller-than-expected quarterly loss may indicate improving financial performance, potentially boosting investor confidence and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About FATE Stock
What is Fate Therapeutics Inc.'s (FATE) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Fate Therapeutics Inc. (FATE) has a median price target of $6.00. The highest price target is $8.00 and the lowest is $2.20.
Is FATE stock a good investment in 2026?
According to current analyst ratings, FATE has 6 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FATE stock?
Wall Street analysts predict FATE stock could reach $6.00 in the next 12 months. This represents a 191.3% increase from the current price of $2.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fate Therapeutics Inc.'s business model?
The company operates in the biopharmaceutical sector, focusing on the development of off-the-shelf cellular immunotherapies utilizing induced pluripotent stem cell (iPSC) technology. It generates revenue through the advancement of its clinical pipeline, which includes several candidates targeting various cancers and autoimmune diseases. Successful clinical trials and subsequent approvals can lead to partnerships, licensing agreements, and ultimately, product sales.
What is the highest forecasted price for FATE Fate Therapeutics Inc.?
The highest price target for FATE is $8.00 from at , which represents a 288.3% increase from the current price of $2.06.
What is the lowest forecasted price for FATE Fate Therapeutics Inc.?
The lowest price target for FATE is $2.20 from at , which represents a 6.8% increase from the current price of $2.06.
What is the overall FATE consensus from analysts for Fate Therapeutics Inc.?
The overall analyst consensus for FATE is neutral. Out of 4 Wall Street analysts, 6 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are FATE stock price projections?
Stock price projections, including those for Fate Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 13, 2026 5:39 AM UTC